Compare Ascendis Pharma A/S (ASND) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Western Alliance Bancorporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Western Alliance Bancorporation trades at $80.69 (market cap $8.81B). The key difference: Ascendis Pharma A/S is far larger — about 2× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays a 2.08% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | WAL | |
|---|---|---|
Market Cap | $17.74B | $8.81B |
Sector | Health | Financials |
52-Week High | $277.18 | $96.08 |
52-Week Low | $163.32 | $66.70 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 2.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Western Alliance Bancorporation (WAL) trades at $80.69, up 0.85% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 9.39 and net income margin of 25.63%, supported by three consecutive quarterly earnings beats. Recent news highlights business expansion, including a $33 million Las Vegas redevelopment loan and recognition as Arizona's top bank by Forbes in 2026.
The outlook is positive given analyst consensus with a $90.67 price target and 79% buy ratings, though risks include negative operating cash flow and high interest expenses. Earnings growth and strategic hires in commercial real estate and entertainment financing present opportunities, but investor caution is warranted near technical resistance at $82.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
